Furosemide injection solution for subcutaneous administration (80 mg)
Sponsors
scPharmaceuticals, Inc., SQ Innovation, Inc.
Conditions
Heart Failure
Phase 1
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
CompletedNCT02350725
Start: 2014-12-31End: 2015-06-30Updated: 2018-06-27
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
CompletedNCT04384653
Start: 2020-10-17End: 2021-06-12Updated: 2026-06-15